SS18-SSX fusion protein (SS18-SSX)

The SS18-SSX (formerly SYT-SSX) fusion protein is a pathognomonic oncoprotein and the primary driver of synovial sarcoma, resulting from the t(X;18)(p11.2;q11.2) chromosomal translocation. This fusion joins the N-terminal portion of the SS18 transcriptional coactivator with the C-terminal portion of an SSX repressor protein (typically SSX1, SSX2, or rarely SSX4). Biologically, the fusion protein hijacks the BAF (SWI/SNF) chromatin remodeling complex, displacing the tumor suppressor subunit BAF47 and mislocalizing the complex to activate bivalent developmental genes like SOX2, which promotes a stem-like oncogenic state. While the protein itself is considered difficult to target directly with small molecules, current therapeutic strategies focus on targeting its essential dependencies, such as BRD9 and WDR5, or inhibiting downstream epigenetic modifiers like EZH2 and HDACs. Successful clinical intervention is further complicated by cellular 'self-protection' mechanisms, where the depletion of the fusion protein can trigger anti-apoptotic signaling pathways.

Other names

SYT-SSX fusion proteinSynovial sarcoma translocation, chromosome 18–Synovial sarcoma, X breakpoint fusion proteint(X;18) translocation productSS18-SSX1SS18-SSX2SS18-SSX4

The SS18-SSX fusion protein acts as an oncogenic driver by integrating into the BAF (SWI/SNF) chromatin remodeling complex, displacing the BAF47 (SMARCB1) subunit and redirecting the complex to activate genes usually silenced by Polycomb group proteins. It also serves as a molecular scaffold bridging the transcription factor ATF2 and the co-repressor TLE1 to repress target genes.